Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 9/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24313037 | 0.87 | CHEK2 (0.61) | CHEK2PLAUPRSS1HDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL11327140 | 0.76 | RHEB (0.46) | CHEK2PLAUPRSS1HDAC6 | |
| SCHEMBL20982708 | 0.76 | HDAC6 (0.63) | PLAUPRSS1HDAC3HDAC1HDAC8 | |
| SCHEMBL10140089 | 0.75 | PLAU (0.48) | CHEK2PLAUPRSS1HDAC3HDAC1 | |
| SCHEMBL7982582 | 0.74 | F10 (0.76) | CHEK2PLAUPRSS1HDAC3HDAC1 | |
| SCHEMBL6179777 | 0.71 | NR4A2 (0.67) | CHEK2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL1663682 | 0.71 | SIRT2 (0.71) | CHEK2SIRT2SIRT1 | |
| SCHEMBL14519390 | 0.70 | PLAU (0.86) | PLAUPRSS1 | |
| SCHEMBL19982678 | 0.70 | CHEK2 (0.74) | CHEK2PLAUPRSS1HDAC3HDAC1 | |
| SCHEMBL24313035 | 0.70 | HDAC6 (0.51) | CHEK2PLAUPRSS1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096441-A1 | TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096441-A1 | TREATMENT OF ACANTHAMOEBA OR BALAMUTHIA TROPHOZOITES AND/OR CYSTS | PKD2, PKD1, MUC1 | CHEK2 241/4885PLAU 959/4885PRSS1 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.